Global scaling for semi-quantitative analysis in FP-CIT SPECT

UNLABELLED Semi-quantitative characterization of dopamine transporter availability from single photon emission computed tomography (SPECT) with 123I-ioflupane (FP-CIT) is based on uptake ratios relative to a reference region. The aim of this study was to evaluate the whole brain as reference region for semi-quantitative analysis of FP-CIT SPECT. The rationale was that this might reduce statistical noise associated with the estimation of non-displaceable FP-CIT uptake. PATIENTS, METHODS 150 FP-CIT SPECTs were categorized as neurodegenerative or non-neurodegenerative by an expert. Semi-quantitative analysis of specific binding ratios (SBR) was performed with a custom-made tool based on the Statistical Parametric Mapping software package using predefined regions of interest (ROIs) in the anatomical space of the Montreal Neurological Institute. The following reference regions were compared: predefined ROIs for frontal and occipital lobe and whole brain (without striata, thalamus and brainstem). Tracer uptake in the reference region was characterized by the mean, median or 75th percentile of its voxel intensities. The area (AUC) under the receiver operating characteristic curve was used as performance measure. RESULTS The highest AUC of 0.973 was achieved by the SBR of the putamen with the 75th percentile in the whole brain as reference. The lowest AUC for the putamen SBR of 0.937 was obtained with the mean in the frontal lobe as reference. CONCLUSION We recommend the 75th percentile in the whole brain as reference for semi-quantitative analysis in FP-CIT SPECT. This combination provided the best agreement of the semi-quantitative analysis with visual evaluation of the SPECT images by an expert and, therefore, is appropriate to support less experienced physicians.

[1]  D. Guilloteau,et al.  Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.

[2]  Ralph Buchert,et al.  IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  G. Pearlson,et al.  Basal ganglia volume in adults with Down syndrome , 1997, Psychiatry Research: Neuroimaging.

[4]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[5]  N. Verhoeff,et al.  Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J D Speelman,et al.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[7]  A. Antonini,et al.  EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.

[8]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[9]  D. Jennings,et al.  Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients , 2007, Journal of Nuclear Medicine.

[10]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Perry E Radau,et al.  Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  G. Knudsen,et al.  Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I , 2010, The Journal of Nuclear Medicine.

[13]  John S. Fleming,et al.  Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Osama Sabri,et al.  Value of Semiquantitative Analysis for Clinical Reporting of 123I-2-β-Carbomethoxy-3β-(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropane SPECT Studies , 2013, The Journal of Nuclear Medicine.

[15]  Z Walker,et al.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.

[16]  K. Tatsch,et al.  Quantitative approaches to dopaminergic brain imaging. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[17]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[18]  D. Brooks,et al.  [123I]β-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson’s disease and multiple system atrophy , 2003, Nuklearmedizin.

[19]  Paul J. Laurienti,et al.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.

[20]  Klaus Tatsch,et al.  Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update , 2013, The Journal of Nuclear Medicine.

[21]  Wim Vandenberghe,et al.  The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  K. Laere,et al.  European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Timmermann,et al.  123I-FP-CIT SPECT imaging of the dopaminergic state , 2012, Nuklearmedizin.

[25]  John Seibyl,et al.  SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.

[26]  W. Koch,et al.  Equipment-independent reference values for dopamine transporter imaging with 123I-FP-CIT , 2007, Nuklearmedizin.

[27]  Sylvain Houle,et al.  Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.

[28]  Dae Hyuk Moon,et al.  Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.